Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06033703 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 28, 2025 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv4 Show 7 more changesShow less
    • Primary completion date: Sep 2025 to Sep 2026
    • Study sites: 0 to 1
    • Study completion date: Dec 2025 to Dec 2026
    • Start date changed from estimate of Dec 2024 to Jan 14, 2025
    • Eligibility criteria shortened, about 12 words
    • Secondary endpoints: details revised at 3 of 5 entries
    • Study description expanded, about 6 words
  2. Primary completion date: Sep 2024 to Sep 2025
    • Start date: Feb 2024 to Dec 2024
    • Study completion date: Dec 2024 to Dec 2025
    v3
  3. Start date: Oct 2023 to Feb 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.
Trial Details
NCT Number NCT06033703
Lead Sponsor Massachusetts Eye and Ear Infirmary
Conditions
(from sponsor)		 Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Related terms Vitreoretinopathy, Proliferative
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov